Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1617 1643 1644 1657 1671
This examiner grants 62% of resolved cases
Karen A. Canella is an examiner in Tech Center 1600 and Art Unit 1617. She has 1139 resolved cases. The allowance rate for these cases is 62.2%, and the interview lift is 32.8%. This 32.8% lift indicates that interviews are associated with a significant increase in the probability of allowance. Practitioners can use the 32.8% lift to improve their chances of securing a grant in her docket.
The median days to allowance is 1272 for the 1139 resolved cases. This 1272-day figure provides a timeline for applications that reach a grant. The 32.8% interview lift suggests that direct communication is a useful tool for reaching the 62.2% allowance rate. With 1139 cases resolved, these metrics offer a basis for managing expectations regarding both the outcome and the 1272-day duration of prosecution in Art Unit 1617.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18280197 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | Non-Final OA | Juno Therapeutics, Inc. |
| 18188380 | METHODS AND COMPOSITIONS FOR DOSING IN ADOPTIVE CELL THERAPY | Non-Final OA | Juno Therapeutics, Inc. |
| 17788993 | INDIVIDUALIZED VACCINES FOR CANCER TREATMENT AND PREVENTION | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 17769917 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT USING NANOPARTICLES CONJUGATED WITH MULTIPLE LIGANDS FOR BINDING RECEPTORS ON NK CELLS | Final Rejection | The University of North Carolina at Chapel Hill |
| 18345385 | Targeted Radiotherapy Chelates for In Situ Immune Modulated Cancer Vaccination | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18297451 | TUMOR VACCINATION IN COMBINATION WITH HEMATOPOIETIC CELL TRANSPLANTATION FOR CANCER THERAPY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18095467 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17356497 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17887828 | UBIQUITIN LIGASE KPC1 PROMOTES PROCESSING OF P105 NF-KAPPAB1 TO P50, ELICITING STRONG TUMOR SUPPRESSION | Non-Final OA | Technion Research & Development Foundation Limited. |
| 18701217 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | Non-Final OA | Bio-Thera Solutions, Ltd. |
| 18691672 | COMPOSITION COMPRISING PD-L1 ANTIGEN-BINDING FRAGMENT AND USE THEREOF | Non-Final OA | SUZHOU ALPHAMAB CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy